Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 vs valsartan in heart failure with preserved ejection fraction (China cohort of PARAGON-HF)
CTR20150051Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Novartis. Started Feb 2015; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20150051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150051.